RxDoctor Payments Data

Nirmala Nanjappa, MD

Internal Medicine · Suffern, NYNPI 1699734970

Payments from drug & device makers

$811in general payments, 2019–2025

Across 54 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$219
  • Teva Pharmaceuticals USA, Inc.$83
  • AbbVie$81
  • Novartis$79
  • AstraZeneca$74
  • Boehringer Ingelheim$53
  • plus $222 from 11 others

What the payments were for

  • Food & beverage$811100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$811 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$246,427
Medicare patients
94
Services billed
3,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate37$55,093
OzempicSemaglutide28$51,640
EliquisApixaban40$50,396
JanumetSitagliptin Phos/Metformin Hcl29$43,310
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$42,935
OxycontinOxycodone Hcl23$22,325
MounjaroTirzepatide13$20,117
Breo ElliptaFluticasone/Vilanterol27$16,267
JardianceEmpagliflozin15$15,394
ViberziEluxadoline12$9,110
EntrestoSacubitril/Valsartan11$7,689
Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid11$5,388
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$4,848
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$3,730
Ibandronate Sodium25$2,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$12$98,40366 claims
GSKTrelegy Ellipta, Breo Ellipta$219$59,20359 claims
Novo NordiskOzempic$35$51,64028 claims
PfizerEliquis$21$50,39640 claims
Boehringer IngelheimJardiance$53$15,39415 claims
AbbVieViberzi$81$9,11012 claims
NovartisEntresto$79$7,68911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Suffern

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →